Renal Anemia Therapeutics Market to Record Growth of USD 2.08 billion from 2023 to 2028, Akebia Therapeutics Inc and Amgen Inc to emerge as Some of the Key Companies - Technavio

29 Jan 2024
www.prnewswire.com
NEW YORK, Jan. 29, 2024 /PRNewswire/ -- The
renal anemia therapeutics market  is estimated to grow by
USD 2.08 billion during 2023-2028, growing at a
For Comprehensive details on the market size of historic period(2018 to 2022) and forecast period (2024-2028) - View the Free Sample report
Continue Reading
Renal Anemia Therapeutics Market to Record Growth of USD 2.08 billion from 2023 to 2028, Akebia Therapeutics Inc and Amgen Inc to emerge as Some of the Key Companies - Technavio
Preview
Source: PRNewswire
Technavio has announced its latest market research report titled Global Renal Anemia Therapeutics Market 2024-2028
The market is fragmented; the companies are competing with competitors and are trying to get greater market share. The market is growing, and chances of new entrants cannot be overlooked. The major companies have well-established economies of scale and presence and generally rely on positioning, technological advances, and the price of the products -
The report provides a full list of key companies, their strategies, and the latest developments. Buy Now
The growing geriatric population drives the growth.  The prevalence of chronic diseases like CKD, is high among the aging population. There is a direct relationship between aging and susceptibility to infections, as it deteriorates the immune system. Apart from the impaired functioning of the immune system, the reduced functioning of organs also increases the chances of acquiring diseases such as CKD.
The growing adoption of biosimilars is an emerging trend shaping growth.
Side effects of oral administration of renal anemia drugs is a major challenge hindering growth.
Technavio has identified key trends, drivers, and challenges, which will help clients improve their strategies to stay ahead of their competitors. - View the Free Sample Report
The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score andperformance score. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others.
Segmentation by Type
The growth by the
IV segment will be significant during the forecast period. The predominant segment is medications administered through the IV route, primarily attributed to the growing adoption and the convenience of absorption. Additionally, ferric carboxymaltose, sucrose, dextran, and other agents like ferumoxytol and isomaltoside contribute to this category.
Gain instant access to 17,000+ research reports.
Technavio's SUBSCRIPTION platform
Applications
The Renal Anemia Therapeutics Market is a dynamic landscape where medical interventions target conditions such as Chronic Kidney Disease (CKD) through a range of treatments. Erythropoiesis-Stimulating Agents (ESAs), including Darbepoetin Alfa and Epoetin Alfa, play a pivotal role in managing anemia associated with renal diseases. Innovative therapies like Roxadustat, a Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) Inhibitor, showcase advancements in addressing anemia linked to CKD. Iron Supplements, both intravenous and oral, are essential components, alongside Ferric Citrate and Ferric Gluconate, contributing to comprehensive anemia management. The market encompasses diverse modalities, from Hemodialysis to Peritoneal Dialysis, recognizing the significance of tailored approaches.
Related Reports
The
hormone replacement therapy (HRT) market size is estimated to grow by USD 8.44 billion, at a CAGR of 6.67% between 2023 and 2028.
The
equine supplement products market size is estimated to grow by USD 20,352.14 at a CAGR of 4.19% between 2023 and 2028.
1 Executive Summary
2 Landscape
3 Sizing
4 Historic Size
5 Five Forces Analysis
6 Segmentation by Type
7 Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Company Landscape
12 Company Analysis
13 Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging trends and provide actionable insights to help businesses identify opportunities and develop effective strategies to optimize their positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable insights to identify opportunities in existing and potential markets and assess their competitive positions within changing scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.